{"nctId":"NCT00535405","briefTitle":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","startDateStruct":{"date":"2007-11"},"conditions":["Hypercholesterolemia"],"count":1289,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Atorvastatin 10 mg"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Ezetimibe 10 mg/simvastatin 20 mg"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Atorvastatin 20 mg"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: Ezetimibe 10 mg/simvastatin 40 mg"]},{"label":"5","type":"EXPERIMENTAL","interventionNames":["Drug: Atorvastatin 40 mg"]}],"interventions":[{"name":"Atorvastatin 10 mg","otherNames":[]},{"name":"Ezetimibe 10 mg/simvastatin 20 mg","otherNames":[]},{"name":"Atorvastatin 20 mg","otherNames":[]},{"name":"Ezetimibe 10 mg/simvastatin 40 mg","otherNames":[]},{"name":"Atorvastatin 40 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has a cholesterol level of 130 mg/dL or greater\n* Patient is willing to maintain a cholesterol lowering diet for as long as they are in the study\n* Patient is at moderate high risk or high risk for coronary heart disease per the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) guidelines\n\nExclusion Criteria:\n\n* Patient weighs less than 100 lbs\n* Patient has an allergy to ezetimibe, simvastatin or atorvastatin","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.5","spread":null},{"groupId":"OG001","value":"-54.2","spread":null},{"groupId":"OG002","value":"-46.6","spread":null},{"groupId":"OG003","value":"-59.1","spread":null},{"groupId":"OG004","value":"-50.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"1.92"},{"groupId":"OG001","value":"51.3","spread":"3.28"},{"groupId":"OG002","value":"26.1","spread":"2.85"},{"groupId":"OG003","value":"68.2","spread":"3.03"},{"groupId":"OG004","value":"38.1","spread":"3.14"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","description":"Patients with AVD Who Achieved LDL-C \\<70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":"3.20"},{"groupId":"OG001","value":"69.0","spread":"3.04"},{"groupId":"OG002","value":"61.3","spread":"3.16"},{"groupId":"OG003","value":"82.1","spread":"2.50"},{"groupId":"OG004","value":"69.9","spread":"2.97"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":"3.17"},{"groupId":"OG001","value":"83.6","spread":"2.43"},{"groupId":"OG002","value":"76.9","spread":"2.73"},{"groupId":"OG003","value":"90.3","spread":"1.93"},{"groupId":"OG004","value":"79.5","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With High Risk for CHD Who Achieved LDL-C <70 mg/dL at Week 12","description":"Risk was assessed utilizing a history of established CHD or CHD risk equivalent and Framingham Risk scoring.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"2.65"},{"groupId":"OG001","value":"54.3","spread":"4.24"},{"groupId":"OG002","value":"28.9","spread":"4.01"},{"groupId":"OG003","value":"69.2","spread":"4.05"},{"groupId":"OG004","value":"38.2","spread":"4.17"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12","description":"Patients with AVD Who Achieved LDL-C \\<70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"3.59"},{"groupId":"OG001","value":"44.4","spread":"5.52"},{"groupId":"OG002","value":"31.6","spread":"5.23"},{"groupId":"OG003","value":"65.8","spread":"5.34"},{"groupId":"OG004","value":"44.4","spread":"5.86"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":257},"commonTop":["Back pain","Nasopharyngitis","Myalgia","Bronchitis","Headache"]}}}